Details of the Drug

General Information of Drug (ID: DM6VOWQ)

• Drug Name: Fomepizole
• Synonyms: Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Athylene glycol or methanol poisoning	NE61	Approved	[1]

• Therapeutic Class: Antidotes
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 82.1
  Topological Polar Surface Area (xlogp); 1.4
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  Absorption: The drug is rapidly and completely absorbed [2]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.73 mL/min/kg [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4.42 hours [3]
  Metabolism: The drug is metabolized via the hepatic [2]
  Vd: The volume of distribution (Vd) of drug is 0.6-1.02 L/kg [4]
• Chemical Identifiers:
  Formula: C4H6N2
  IUPAC Name: 4-methyl-1H-pyrazole
  Canonical SMILES: CC1=CNN=C1
  InChI: InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)
  InChIKey: RIKMMFOAQPJVMX-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3406
  ChEBI ID: CHEBI:5141
  CAS Number: 7554-65-6
  DrugBank ID: DB01213
  TTD ID: D02NJA
  INTEDE ID: DR0743

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alcohol dehydrogenase 1A (ADH1A)	TT5AHZ0	ADH1A_HUMAN	Modulator	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1) Main DME	DEVDYN7	CP2E1_HUMAN	Substrate	[6]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole. Open Access Emerg Med. 2010 Aug 24;2:67-75.
• [7] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [8] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [9] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [10] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [11] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [12] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [13] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [14] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [15] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [16] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.